The value of local 99mTc(Sn)-MDP bone to soft tissue uptake ratio in osteoporosis, before and during fluoride therapy.
The reproducibility and diagnostic value of local bone to soft tissue uptake ratio of 99mTc(Sn)-MDP as a bone tracer was examined in a prospective study in 35 patients who were under investigation and/or treatment for postmenopausal osteoporosis. The ratio of tracer uptake in the second lumbar vertebra (L2) and both femoral shafts was calculated from the number of counts in suitable regions of interest. Results obtained with settings and calculations in the routine practice were compared to the results obtained by revision of all raw data in one run by one person. The results were compared to the serum alkaline phosphatase activity (AP) and to local bone mineral mass as determined by dual photon absorptiometry (DPA). In 15 patients serial measurements during fluoride therapy were also compared to serum osteocalcin values and to bone histomorphometric data. The precision error of the calculation of uptake ratios from raw counts (including selection of region of interest) was 13.9% for the femoral shaft and 14.7% for L2. The mean difference between left and right femoral shaft in individuals was not significant and its variance was small P greater than 0.1). There was a weak but significant linear correlation between local uptake ratio in the spine and AP in the total material (r = 0.328 P less than 0.01). However, changes in local uptake ratio during therapy with fluoride in 15 patients were too small to be of any value and did not correlate with changes in alkaline phosphatase or osteocalcin or trabecular surface covered with osteoblasts.(ABSTRACT TRUNCATED AT 250 WORDS)
Raymakers
J A
JA
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
Savelkoul
T J
TJ
Hoekstra
A
A
Visser
W J
WJ
van Rijk
P P
PP
Duursma
S A
SA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism*; D003238:Connective Tissue / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D011877:Radionuclide Imaging; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000627:therapeutic use*; D013608:Tablets, Enteric-Coated; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics*
D013608:Tablets, Enteric-Coated; C023568:technetium Tc 99m (Sn)methylenediphosphonate; D012969:Sodium Fluoride; D013669:Technetium Tc 99m Medronate